Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424) expects to see a 17.05 percent year-on-year increase in its 2017 operating revenue, as shown in its preliminary financial report released Tuesday.
This preview shows a total operating revenue of RMB 2.5918 billion for this company.
Profits attributable to its shareholders stand at RMB 526.0676 million, up by 9.07 percent year-on-year. Earnings per share rose to RMB 2.42, up by 13.08 percent.
As of the end of 2017, its total assets stood at RMB 4.8226 billion, up by 13.85 percent year-on-year. Equities attributable to its shareholders totaled RMB 3.4197 billion, up by 13.18 percent.
The 9.07 percent growth in profits attributable to its shareholders falls short of that forecasted in its third-quarter report, which was put at a range of 10 percent to 40 percent.
This discrepancy was mainly due to increased investments in the development of new medicine as well as higher sales expenses incurred in the company’s efforts to enhance its sales network, compliance system, and marketing strategy.
These data were audited only internally and may be subject to further adjustments in its final 2017 performance report.
This preview shows a total operating revenue of RMB 2.5918 billion for this company.
Profits attributable to its shareholders stand at RMB 526.0676 million, up by 9.07 percent year-on-year. Earnings per share rose to RMB 2.42, up by 13.08 percent.
As of the end of 2017, its total assets stood at RMB 4.8226 billion, up by 13.85 percent year-on-year. Equities attributable to its shareholders totaled RMB 3.4197 billion, up by 13.18 percent.
The 9.07 percent growth in profits attributable to its shareholders falls short of that forecasted in its third-quarter report, which was put at a range of 10 percent to 40 percent.
This discrepancy was mainly due to increased investments in the development of new medicine as well as higher sales expenses incurred in the company’s efforts to enhance its sales network, compliance system, and marketing strategy.
These data were audited only internally and may be subject to further adjustments in its final 2017 performance report.
Latest comments